Stockscreener 앱 받기
58.11
2.12%
-1.26
시간 외 거래:
58.24
0.13
+0.22%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Swiss Life Asset Management Ltd Purchases 68,565 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Wilmington Savings Fund Society FSB Has $5.24 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 - The Joplin Globe
Bristol-Myers Squibb Co Stock (ISIN: US1101221083) Faces Mixed Signals After Q4 Earnings Miss Amid S - AD HOC NEWS
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Cadillac News
BMS brings ‘Emily in Paris’ star and cancer survivor Ashley Park aboard campaign honoring oncologists - Fierce Pharma
Merck vs. Bristol Myers: Which pharma stock is a better pick in 2026? - MSN
WBI Investments LLC Has $2.70 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
US FDA approves J&J's oral psoriasis pill - Reuters
Danske Bank A S Makes New $71.59 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stake Boosted by Achmea Investment Management B.V. - MarketBeat
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Physician Views Preview: Can BMS' Sotyktu provide a new oral standard of care for psoriatic arthritis? - FirstWord Pharma
Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study - TipRanks
Jefferies raises Bristol-Myers Squibb stock price target on trial data - Investing.com
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60 - 富途牛牛
Bristol Myers Squibb Company $BMY Stock Position Increased by Gotham Asset Management LLC - MarketBeat
Bristol Myers Squibb Company $BMY Stock Position Decreased by Brevan Howard Capital Management LP - MarketBeat
Raymond James reiterates Market Perform on Bristol-Myers Squibb stock By Investing.com - Investing.com Canada
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Raymond James reiterates Market Perform on Bristol-Myers Squibb stock - Investing.com
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - TradingView
Chevy Chase Trust Holdings LLC Sells 35,963 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BNP Paribas Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Cannell & Spears LLC Has $11.41 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Acquired by Aquatic Capital Management LLC - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Has $29.60 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Ameriprise Financial Inc. Has $1.46 Billion Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
M&T Bank Corp Has $34.43 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Prudential PLC Acquires 36,159 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY is Independent Franchise Partners LLP's 2nd Largest Position - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Dodge & Cox - MarketBeat
Cadence Bank Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to make immune cell cancer therapies in Japan - Nikkei Asia
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Quadrature Capital Ltd Purchases Shares of 532,436 Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Martingale Asset Management L P - MarketBeat
Mackenzie Financial Corp Buys 149,701 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
143,691 Shares in Bristol Myers Squibb Company $BMY Acquired by Entropy Technologies LP - MarketBeat
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors - ChartMill
Bristol Myers Squibb Company $BMY Shares Sold by Employees Retirement System of Texas - MarketBeat
Bokf Na Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Arrowstreet Capital Limited Partnership Has $669.01 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Colgate-Palmolive Elects Christopher Boerner, Ph.D. to Board of Directors - citybiz
Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board By Investing.com - Investing.com India
Bristol Myers CEO joins Colgate-Palmolive (NYSE: CL) board - Stock Titan
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - The Globe and Mail
KLCM Advisors Inc. Sells 17,799 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by Franklin Resources Inc. - MarketBeat
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry - Insider Monkey
Citi Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Capital International Sarl Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Capital Group Private Client Services Inc. - MarketBeat
UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms - Finviz
Van ECK Associates Corp Acquires 3,982,439 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
LGT Fund Management Co Ltd. Has $372,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Readies New Growth Drivers In Immunology And Cancer - simplywall.st
Assessing Bristol Myers Squibb (BMY) Valuation As Growth Portfolio Drives Revenue And Earnings Reset - Yahoo Finance
Bristol Myers Squibb (NYSE:BMY) Boosts Research Strengthening S&P 500 Index Momentum - Kalkine Media
BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis - Finviz
Schroder Investment Management Group Has $548.82 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Cancer Drug Achieves Key Goal in Phas - GuruFocus
Bristol Myers Squibb reports positive phase 3 trial results - Investing.com
0.33%
0.99%
자본화:
|
볼륨(24시간):